Navigation Links
BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
Date:10/24/2007

SAN FRANCISCO, Oct. 24 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced data demonstrating that BSI-401 inhibited pancreatic cancer cell growth in vitro and in vivo, both alone and in combination with oxaliplatin. BSI-401 is BiPar's second-generation product in a new class of cancer therapies known as PARP (poly-ADP-ribose polymerase) inhibitors.

Researchers presented the data at the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics in San Francisco.

"These results demonstrate the potential of BSI-401 to treat one of the most deadly and difficult-to-treat cancers," said James L. Abbruzzese, professor of gastrointestinal medical oncology and associate medical director of the gastrointestinal center at the University of Texas M.D. Anderson Cancer Center, who helped conduct the research. "Because of PARP's role in DNA repair, inhibitors of the protein may make tumors more sensitive to oxaliplatin, which induces breaks in DNA strands, and could also be powerful enough to act as a targeted monotherapy."

Pancreatic cancer kills more than 30,000 each year in the United States. Patients with advanced pancreatic cancer do not usually survive a year after diagnosis, and the limited therapeutic options have made improved treatments a major unmet need in oncology.

In animals with orthotopic human pancreatic tumors, BSI-401 administered significantly reduced tumor burden and extended survival. In addition, a synergistic effect was seen with BSI-401 in combination with oxaliplatin.

PARP is a well-characterized and validated target for cancer therapies. PARP-1 plays a central role in cell proliferation in DNA repair, and the PARP-1 gene is upregulated in certain tumor types.

BiPar's novel, proprietary PARP inhibit
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015  Seeger Weiss LLP is reporting that on July ... letter to C.R. Bard, the manufacturer of Inferior vena ... correct violations the agency found at two of Bard,s facilities. ... FDA cited them during Inspectional Observations that occurred on November ... Tempe, AZ , location and on October 6, 2014, ...
(Date:7/31/2015)... RnRMarketResearch.com adds Syringes and ... that provides an overview of syringes and needles ... in-house databases, secondary and primary research. ... pipeline spread across 124 pages, talking about 13 ... 5 figures is now available at http://www.rnrmarketresearch.com/syringes-and-needles-pipeline-review-2015-market-report.html ...
(Date:7/31/2015)... According to a new market research report " Sterilization ... Filtration, E-beam, Gamma), Services (Onsite & Offsite), Consumables (Indicators, Detergents, ... 2020", published by MarketsandMarkets, The Sterilization Equipment Market is expected ... CAGR of 7.6%.from 2015 to 2020. Browse ... and 37 F igures spread ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4
... NEW BRUNSWICK, N.J., Jan. 14, 2011 McNeil Consumer Healthcare ... JNJ ) company, in July 2010 submitted to the ... a commitment to restore its operations to the level of ... Johnson companies. As part of this commitment, McNeil undertook a ...
... 2011 New clinical research data suggests that [18F] ... by physicians and provide accurate identification of beta amyloid ... to Alzheimer,s Disease (AD).  Flutemetamol, a GE Healthcare Positron ... development, is being studied to identify the uptake of ...
Cached Medicine Technology:Johnson & Johnson Provides Update on McNeil Consumer Healthcare Remediation; Announces Completion of Internal Assessment Phase of Comprehensive Action Plan 2GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease 2GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease 3
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... Girl ... stamp out bullying across Georgia through the Girl Scout "Be a Friend First" program. ... on Thursday, July 30. , “Peach State Health Plan and our parent company, ...
(Date:7/31/2015)... , ... July 31, 2015 , ... The Mount Sinai ... research projects that evaluate the potential of related, experimental treatments. The collaboration moves into ... Health to award Columbia Care one of five state licenses to produce and dispense ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... BioViva USA, ... the way we treat aging diseases. , BioViva announces it has begun a ... patients with Alzheimer’s Disease (AD) and find a cure. MaxLife will grant 100% of ...
(Date:7/31/2015)... ... 2015 , ... Recently, ZKB filed another federal lawsuit in ... No. 3:15-cv-00397) involving the Implanon® contraceptive implant . , As described in ... implants, inability to locate the implants, unsuccessful and invasive attempts at implant removal, ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Heart Fit Clinic has ... angina until a heart rate of 150 beats versus 100 beats, this is a ... are able to give life back to patients with heart disease," he adds. People ...
Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2
... form "MaxLife-CGP",Partners LLC., a California based operation. "MaxLife-CGP" expects to ... face value, of which the Joint Venture anticipates ... ... /PRNewswire-FirstCall/ - MaxLife Fund Corp.,(OTC:MXFD). MaxLife Fund Corp. ("MaxLife") and ...
... Michael Aram,will lend his support to another noteworthy cause, The ... his flagship store on March,13th for a special benefit event., ... based charity that was,established in 1994, at a time when ... committed itself to raising awareness on and,preventing the local spread ...
... facility doubles US Phase I capacity, RALEIGH, N.C., ... has announced the grand opening of its,expanded, newly built ... the occasion with a special event at the facility ... Pharmacology Center,s size to 80,beds, with the clinic occupying ...
... Feb. 25 Weight Watchers,International, Inc. (NYSE: WTW ... Officer, and Ann Sardini, Chief Financial,Officer, will present at ... NY., The presentation will be held on Tuesday, ... be accessible via live audio webcast on the Company,s,website ...
... advocates have received the inaugural Omololu Falobi Award for ... awards honor the late Omololu Falobi, a long-time HIV ... Nigeria, was an instrumental pioneer member of the Nigerian ... & Microbicide Advocacy Group. Omololu was killed in ...
... LOS ANGELES, Feb. 25 Most Oscar pundits are ... Stars,",Michael Kosdon watched this year,s Academy Awards with a ... difference between bright, white camera-ready smiles and simply,adequate smiles ... Dr. Kosdon from his own Oscar party at The ...
Cached Medicine News:Health News:MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement 2Health News:MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement 3Health News:Weight Watchers to Present at Bank of America 2008 Consumer Conference 2Health News:Omololu Falobi Awards for Excellence in HIV Prevention Research Community Advocacy presented 2Health News:Omololu Falobi Awards for Excellence in HIV Prevention Research Community Advocacy presented 3
6 inch hand held occlcuder with 49 holes...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Short handle occluders are about 6 inches long....
Manual Lensmeter....
Medicine Products: